Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer

Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck ar...

Full description

Saved in:
Bibliographic Details
Main Authors: D. M. Vontlaya, O. V. Stryapikhina, A. A. Egorin, A. V. Logvinenko, R. I. Tamrazov
Format: Article
Language:Russian
Published: ABV-press 2024-06-01
Series:Опухоли головы и шеи
Subjects:
Online Access:https://ogsh.abvpress.ru/jour/article/view/970
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850024052608991232
author D. M. Vontlaya
O. V. Stryapikhina
A. A. Egorin
A. V. Logvinenko
R. I. Tamrazov
author_facet D. M. Vontlaya
O. V. Stryapikhina
A. A. Egorin
A. V. Logvinenko
R. I. Tamrazov
author_sort D. M. Vontlaya
collection DOAJ
description Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia.The article describes a clinical case of a response of unresectable, BRAF-negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.
format Article
id doaj-art-442e4c998bc340a082940c0c66a1cbcd
institution DOAJ
issn 2222-1468
2411-4634
language Russian
publishDate 2024-06-01
publisher ABV-press
record_format Article
series Опухоли головы и шеи
spelling doaj-art-442e4c998bc340a082940c0c66a1cbcd2025-08-20T03:01:13ZrusABV-pressОпухоли головы и шеи2222-14682411-46342024-06-01141636910.17650/2222-1468-2024-14-1-63-69587Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancerD. M. Vontlaya0O. V. Stryapikhina1A. A. Egorin2A. V. Logvinenko3R. I. Tamrazov4Multidisciplinary clinical medical center “Medical city”Tyumen State Medical University, Ministry of Health of RussiaMultidisciplinary clinical medical center “Medical city”Multidisciplinary clinical medical center “Medical city”Multidisciplinary clinical medical center “Medical city”Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia.The article describes a clinical case of a response of unresectable, BRAF-negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.https://ogsh.abvpress.ru/jour/article/view/970anaplastic thyroid cancerthyroid glandimmunotherapypembrolizumab
spellingShingle D. M. Vontlaya
O. V. Stryapikhina
A. A. Egorin
A. V. Logvinenko
R. I. Tamrazov
Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
Опухоли головы и шеи
anaplastic thyroid cancer
thyroid gland
immunotherapy
pembrolizumab
title Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
title_full Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
title_fullStr Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
title_full_unstemmed Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
title_short Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
title_sort rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
topic anaplastic thyroid cancer
thyroid gland
immunotherapy
pembrolizumab
url https://ogsh.abvpress.ru/jour/article/view/970
work_keys_str_mv AT dmvontlaya rareclinicalobservationofpronouncedresponsetoimmunotherapyinapatientwithanaplasticthyroidcancer
AT ovstryapikhina rareclinicalobservationofpronouncedresponsetoimmunotherapyinapatientwithanaplasticthyroidcancer
AT aaegorin rareclinicalobservationofpronouncedresponsetoimmunotherapyinapatientwithanaplasticthyroidcancer
AT avlogvinenko rareclinicalobservationofpronouncedresponsetoimmunotherapyinapatientwithanaplasticthyroidcancer
AT ritamrazov rareclinicalobservationofpronouncedresponsetoimmunotherapyinapatientwithanaplasticthyroidcancer